Prostate Cancer

Top Story

Industry payments not linked with prescription of prostate cancer drugs

August 21, 2017
Test.docx Oncologists and urologists who received payments from the pharmaceutical industry did not write a larger number of prescriptions for major prostate cancer drugs than those who did not, according to findings published in Cancer. “Abiraterone and enzalutamide are the 2 most widely prescribed drugs for metastatic castration-resistant prostate cancer, with $2.2 billion and $1.
In the Journals

Elevated MI, stroke risk common with newly diagnosed cancer

August 15, 2017
Patients with newly diagnosed cancer have elevated risk for MI and stroke, particularly in the first 6 months after diagnosis, according to data published in the…
In the Journals Plus

Older patients with cancer may burden caregivers by overestimating physical abilities

August 14, 2017
Older patients with cancer often reported having better physical function, mental health and social support than their caregivers’ assessments, according to study…
Meeting News

Guest Commentary: Resistance to androgen-targeting agents highlights unmet need in prostate cancer

August 10, 2017
In this guest commentary, Leonard J. Appleman, MD, PhD, of the division of hematology/oncology at the University of Pittsburgh Medical Center Hillman
More Headlines »

Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies

This activity is supported by an educational grant from Bristol-Myers Squibb.

Incidence rates of melanoma in the United States continue to rise, with an estimated 87,110 new cases being diagnosed…
More »
Meeting News

VIDEO: Results of LATITUDE trial reinforce long-hypothesized theory in prostate cancer treatment

June 21, 2017
More »
Resource Centers


Diagnostic and Therapeutic Challenges in Von Willebrand Disease

This activity is supported by an educational grant from Shire.

With the significant variability in the subtypes and clinical manifestations of von Willebrand disease (VWD), diagnosis…
More »